Market cap and P/E at the last close; sales growth is the latest quarter on the same quarter a year before; ROE for the latest financial year.
From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.
In ₹ Crore except Per Share Latest Annual | SURAKSHA FY26 | KRSNAA FY26 | HEALTHX FY26 | NEPHROPLUS FY26 | Peer Average | |
|---|---|---|---|---|---|---|
| Valuation — at last close | ||||||
| P/E | 51.71× | ◆ 15.91× | 754.59× | 74.12× | 281.54× -82% | |
| P/B | 6.80× | 1.65× | ◆ 1.39× | 5.65× | 2.89× +135% | |
| EV/EBITDA | 17.17× | 8.44× | ◆ -19.27× | 26.26× | 5.14× +234% | |
| Market Cap | ₹1,664 Cr | ₹1,615 Cr | ₹888 Cr | ₹6,307 Cr | ₹2,937 Cr -43% | |
| Growth | ||||||
| Revenue CAGR 3Y | — | ◆ 16.63% | 8.26% | — | 12.45% | |
| Revenue CAGR 5Y | — | — | 19.20% | — | 19.20% | |
| Net Income CAGR 3Y | — | 17.76% | — | — | 17.76% | |
| Revenue YoY (latest Q) | 20.75% | 22.05% | ◆ 49.73% | — | 35.89% -42% | |
| Net Income YoY (latest Q) | ◆ 40.00% | -19.34% | -92.53% | — | -55.94% +172% | |
| Profitability | ||||||
| EBITDA Margin | ◆ 30.73% | 27.42% | -3.95% | 22.72% | 15.40% +100% | |
| Net Income Margin | 10.12% | ◆ 13.13% | -0.11% | 7.69% | 6.90% +47% | |
| Return on Common Equity | ◆ 14.11% | 10.89% | 0.18% | 6.88% | 5.98% +136% | |
| Return on Capital Employed | ◆ 15.88% | 9.62% | — | 11.63% | 10.63% +49% | |
| Return on Assets | ◆ 8.04% | 6.53% | -0.15% | 5.22% | 3.87% +108% | |
| Credit & Quality | ||||||
| Total Debt/Equity | ◆ 0.01× | 0.55× | 0.03× | 0.07× | 0.22× -95% | |
| Interest Coverage | ◆ 4.30× | 3.53× | -75.12× | 2.26× | -23.11× +119% | |
| Scale — latest FY | ||||||
| Revenue / Total Income | ₹310 Cr | ₹773 Cr | ₹1,319 Cr | ₹999 Cr | ₹1,030 Cr -70% | |
| Net Income | ₹31.4 Cr | ₹101 Cr | −₹1.4 Cr | ₹76.8 Cr | ₹58.9 Cr -47% | |
| Total Assets | ₹448 Cr | ₹1,824 Cr | ₹936 Cr | ₹1,471 Cr | ₹1,410 Cr -68% | |
| EPS | ₹6.18 | ₹31.3 | ₹0.37 | ₹8.48 | ₹13.38 -54% | |
| Book Value per Share | ₹47.01 | ₹302.23 | ₹201.47 | ₹111.27 | ₹204.99 -77% | |